Literature DB >> 22968369

Neuropathologically defined subtypes of Alzheimer's disease differ significantly from neurofibrillary tangle-predominant dementia.

Nicholas J Janocko1, Kevin A Brodersen, Alexandra I Soto-Ortolaza, Owen A Ross, Amanda M Liesinger, Ranjan Duara, Neill R Graff-Radford, Dennis W Dickson, Melissa E Murray.   

Abstract

Alzheimer's disease (AD) can be classified based on the relative density of neurofibrillary tangles (NFTs) in the hippocampus and association cortices into three subtypes: typical AD, hippocampal-sparing AD (HpSp AD), and limbic-predominant AD (LP AD). AD subtypes not only have pathologic, but also demographic, clinical, and genetic differences. Neurofibrillary tangle-predominant dementia (NFTD), a disorder with NFTs relatively restricted to limbic structures, shares this feature with LP AD raising the possibility that NFTD is a variant of AD. The objective criteria for pathologic diagnosis of NFTD are not available. A goal of this study was to design a mathematical algorithm that could diagnose NFTD from NFT and senile plaque (SP) counts in hippocampus and association cortices, analogous to that used to subtype AD. Moreover, we aimed to compare pathologic, demographic, clinical, and genetic features of NFTD (n = 18) with LP AD (n = 19), as well as the other AD subtypes, typical AD (n = 52) and HpSp AD (n = 17). Using digital microscopy, we confirmed that burden of phospho-tau (CP13) and of an NFT conformational epitope (Ab39) correlated with NFT densities and showed expected patterns across AD subtypes. HpSp AD had the highest and LP AD had the lowest burden of cortical CP13 and Ab39 immunoreactivity. On the other hand, cortical β-amyloid burden did not significantly differ between AD subtypes. Semi-quantitative assessment of SPs in the basal ganglia did show HpSp AD to have significantly more frequent presence of SPs compared to typical AD, which was more frequent than LP AD. Compared to LP AD, NFTD had an older age at disease onset and shorter disease duration, as well as lower Braak NFT stage. NFTs and SPs on thioflavin-S fluorescent microscopy, as well as CP13, Ab39, and Aβ immunoreactivities were very low in the frontal cortex of NFTD, differentiating NFTD from AD subtypes, including LP AD. MAPT H1H1 genotype frequency was high (~70 %) in NFTD and LP AD, and similar to typical AD, while APOE ε4 carrier state was low in NFTD. While it shares clinical similarities with regard to female sex predominance, onset in advanced age, and a slow cognitive decline, NFTD has significant pathologic differences from LP AD, suggesting that it may not merely be a variant of AD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968369      PMCID: PMC3483034          DOI: 10.1007/s00401-012-1044-y

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  41 in total

1.  Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases.

Authors:  C J Galton; K Patterson; J H Xuereb; J R Hodges
Journal:  Brain       Date:  2000-03       Impact factor: 13.501

2.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

3.  Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank.

Authors:  Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Oct-Dec       Impact factor: 2.703

4.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

Authors:  Melissa E Murray; Neill R Graff-Radford; Owen A Ross; Ronald C Petersen; Ranjan Duara; Dennis W Dickson
Journal:  Lancet Neurol       Date:  2011-07-27       Impact factor: 44.182

5.  The MAPT H1 haplotype is associated with tangle-predominant dementia.

Authors:  Ismael Santa-Maria; Aya Haggiagi; Xinmin Liu; Jessica Wasserscheid; Peter T Nelson; Ken Dewar; Lorraine N Clark; John F Crary
Journal:  Acta Neuropathol       Date:  2012-07-17       Impact factor: 17.088

6.  Diagnosis of Alzheimer's disease.

Authors:  Z S Khachaturian
Journal:  Arch Neurol       Date:  1985-11

7.  Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease.

Authors:  D S Knopman; C R Jack; H J Wiste; S D Weigand; P Vemuri; V Lowe; K Kantarci; J L Gunter; M L Senjem; R J Ivnik; R O Roberts; B F Boeve; R C Petersen
Journal:  Neurology       Date:  2012-05-02       Impact factor: 9.910

8.  NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC).

Authors:  Osamu Yokota; Seishi Terada; Hideki Ishizu; Kuniaki Tsuchiya; Yoshihiro Kitamura; Kenji Ikeda; Kenji Uéda; Shigetoshi Kuroda
Journal:  Acta Neuropathol       Date:  2002-05-08       Impact factor: 17.088

9.  Argyrophilic grain disease is a sporadic 4-repeat tauopathy.

Authors:  Takashi Togo; Naruhiko Sahara; Shu-Hui Yen; Natalie Cookson; Takashi Ishizawa; Mike Hutton; Rohan de Silva; Andrew Lees; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2002-06       Impact factor: 3.685

10.  Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis.

Authors:  Jennifer L Whitwell; Clifford R Jack; Scott A Przybelski; Joseph E Parisi; Matthew L Senjem; Bradley F Boeve; David S Knopman; Ronald C Petersen; Dennis W Dickson; Keith A Josephs
Journal:  Neurobiol Aging       Date:  2009-11-14       Impact factor: 4.673

View more
  58 in total

1.  TDP-43 is a key player in the clinical features associated with Alzheimer's disease.

Authors:  Keith A Josephs; Jennifer L Whitwell; Stephen D Weigand; Melissa E Murray; Nirubol Tosakulwong; Amanda M Liesinger; Leonard Petrucelli; Matthew L Senjem; David S Knopman; Bradley F Boeve; Robert J Ivnik; Glenn E Smith; Clifford R Jack; Joseph E Parisi; Ronald C Petersen; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-03-23       Impact factor: 17.088

2.  Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease.

Authors:  Val J Lowe; Emily S Lundt; Sabrina M Albertson; Scott A Przybelski; Matthew L Senjem; Joseph E Parisi; Kejal Kantarci; Bradley Boeve; David T Jones; David Knopman; Clifford R Jack; Dennis W Dickson; Ronald C Petersen; Melissa E Murray
Journal:  Alzheimers Dement       Date:  2019-06-04       Impact factor: 21.566

Review 3.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

4.  Increased tau phosphorylation follows impeded dopamine clearance in a P301L and novel P301L/COMT-deleted (DM) tau mouse model.

Authors:  Jeremy Koppel; Heidy Jimenez; Leslie Adrien; Eric H Chang; Anil K Malhotra; Peter Davies
Journal:  J Neurochem       Date:  2018-11-12       Impact factor: 5.372

5.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

6.  Severe amygdala dysfunction in a MAPT transgenic mouse model of frontotemporal dementia.

Authors:  Casey Cook; Judy H Dunmore; Melissa E Murray; Kristyn Scheffel; Nawsheen Shukoor; Jimei Tong; Monica Castanedes-Casey; Virginia Phillips; Linda Rousseau; Michael S Penuliar; Aishe Kurti; Dennis W Dickson; Leonard Petrucelli; John D Fryer
Journal:  Neurobiol Aging       Date:  2013-12-26       Impact factor: 4.673

7.  Clinicopathological outcomes of prospectively followed normal elderly brain bank volunteers.

Authors:  Brittany N Dugger; Joseph G Hentz; Charles H Adler; Marwan N Sabbagh; Holly A Shill; Sandra Jacobson; John N Caviness; Christine Belden; Erika Driver-Dunckley; Kathryn J Davis; Lucia I Sue; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2014-03       Impact factor: 3.685

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

Review 9.  Case Studies Illustrating Focal Alzheimer's, Fluent Aphasia, Late-Onset Memory Loss, and Rapid Dementia.

Authors:  Gamze Balci Camsari; Melissa E Murray; Neill R Graff-Radford
Journal:  Neurol Clin       Date:  2016-06-03       Impact factor: 3.806

Review 10.  Neuropathological assessment of the Alzheimer spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2020-08-01       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.